|1.||Vad, Nikhil M: 3 articles (10/2010 - 05/2008)|
|2.||Moridani, Majid Y: 3 articles (10/2010 - 05/2008)|
|3.||McDonald, Jay M: 2 articles (09/2015 - 02/2009)|
|4.||Chen, Yabing: 2 articles (09/2015 - 02/2009)|
|5.||Grover, Sandeep: 2 articles (01/2012 - 01/2012)|
|6.||Luo, Fang: 2 articles (08/2009 - 04/2008)|
|7.||Chen, Yan: 2 articles (08/2009 - 04/2008)|
|8.||Yang, Cheng: 2 articles (08/2009 - 04/2008)|
|9.||Wang, Zaijie Jim: 2 articles (08/2009 - 04/2008)|
|10.||Shin, Soon Young: 2 articles (07/2006 - 08/2004)|
|1.||Schizophrenia (Dementia Praecox)
05/01/1962 - "Efficacy of trifluoperazine on withdrawal in chronic schizophrenia."
01/01/2014 - "Large, independent trials are needed that adhere to the CONSORT statement to compare trifluoperazine with placebo used in the treatment of schizophrenia and schizophrenia-like illnesses."
01/01/2014 - "All available clinical randomised trials involving people with schizophrenia and schizophrenia-like illnesses that compare trifluoperazine with placebo. "
01/01/2004 - "It has been claimed that trifluoperazine is effective at low doses for patients with schizophrenia but this does not appear to be based on good quality trial based evidence."
01/01/2004 - "All clinical randomised trials involving people with schizophrenia and comparing trifluoperazine with any other treatment. "
01/01/2015 - "Treatment of cancer cells with trifluoperazine significantly reduces angiogenesis and prevents cancer cell invasion through a chorioallantoic basement membrane. "
01/01/2015 - "One hit, trifluoperazine, suppresses invasion of human cancer cell lines while displaying a limited cytotoxicity profile. "
12/01/2012 - "We demonstrated that trifluoperazine inhibited CSC tumor spheroid formation and down-regulated the expression of CSC markers (CD44/CD133). "
01/01/2015 - "Taken together, we demonstrated that trifluoperazine is responsible for reducing the angiogenic and invasive potential of aggressive cancer cells through dopamine receptor D2 to modulate the β-catenin pathway and propose that trifluoperazine may be used as an antimetastasis chemotherapeutic."
11/01/2014 - "Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades."
12/01/1997 - "The results demonstrate that trifluoperazine markedly reduces infarct volume after 2 hours of MCA occlusion when given 5 minutes after the induction of ischemia. "
12/01/1997 - "Trifluoperazine, given at 5 minutes after ischemia, had no influence on blood flow in the neocortical penumbra during and after ischemia. "
12/01/1997 - "Trifluoperazine (5.0 mg.kg-1) was injected intraperitoneally 5 minutes, 1 hour, or 2 hours after the induction of ischemia. "
12/06/2002 - "Cyclosporin A (CsA) and trifluoperazine, which reportedly inhibit the I/R elicited opening of a mitochondrial permeability transition (MPT) pore, were very effective in suppressing ischemia/reperfusion evoked release of all six FFAs. "
09/01/1988 - "To investigate the role of Ca-calmodulin complex in the development of myocardial injury caused by ischemia and reperfusion, an isolated working rat hearts were subjected to ischemia/reperfusion with and without calmodulin antagonist, trifluoperazine (TFP 5 x 10(-7)M) in the perfusion medium. "
07/01/1996 - "Trifluoperazine (TFP) and chlorpromazine (CPZ), two pharmacologically active phenotiazine derivatives, were evaluated for their inhibitory activity on the replication of the arenaviruses Junin (JV), the etiological agent of Argentine hemorrhagic fever, Tacaribe virus and Pichinde virus. "
01/01/1988 - "[Synergism in the cytotoxic action of a combination of bleomycin, hyperthermia and trifluoperazine]."
01/01/1986 - "We have reported in the preceding paper that the treatment of plateau phase mouse EMT6 tumour cells with a combination of hyperthermia (HT; 44 degrees C) and trifluoperazine (TFP; 30 micrograms ml-1; an inhibitor of calmodulin) greatly enhances the cytotoxicity of the antitumour drug belomycin (BLM). "
08/01/1986 - "To improve the efficacy of thermochemotherapy we have investigated the individual and combined effects of hyperthermia (44 degrees C) and the calmodulin inhibitor trifluoperazine (30 micrograms/ml) on early plateau phase cultures of mouse EMT6 cells for simultaneous exposures to bleomycin. "
01/01/1986 - "Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity."
04/01/2008 - "In addition, trifluoperazine (i.p.) dose-dependently reversed CFA-induced mechanical allodynia and thermal hyperalgesia. "
08/01/2009 - "Trifluoperazine (administered intraperitoneally or by mouth) dose-dependently reversed SNL-induced mechanical allodynia, thermal hyperalgesia, and CaMKII activation without causing locomotor impairment in mice at the highest doses used. "
02/01/2002 - "Intrathecal trifluoperazine (1, 10, 100 microg) showed a biphasic effect in the formalin test; i.e., analgesia at relatively low doses (1, 10 microg) and hyperalgesia at a high dose (100 microg). "
01/01/2012 - "Similarly, oral administration of trifluoperazine (0.1 and 0.3 mg/kg, p.o.), which is an antipsychotic drug and inhibits calmodulin, reduced both mechanical allodynia and increased CaMKII phosphorylation. "
01/01/2012 - "These results suggest that CaMKII is involved in the oxaliplatin-induced mechanical allodynia, and trifluoperazine may be useful for the treatment of oxaliplatin-induced peripheral neuropathy in clinical setting."
|1.||Calmodulin (Calcium-Dependent Activator Protein)
|7.||P-30 composite resin (P 30)
|9.||Calcium-Calmodulin-Dependent Protein Kinase Type 2
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Combination Drug Therapy (Combination Chemotherapy)
|5.||Cardiopulmonary Resuscitation (CPR)